New Retina Radio
New Retina Radio

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression? David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observed?  And Ehsan Rahimy, MD, reviews findings from a retrospective analysis seeking to understand if continuous glucose monitoring could reduce the risk of NPDR progressing to more serious conditions. Listen in to learn what he and his colleagues found.  

View full description +

MORE EPISODES

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

08.21.25

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

John Kitchens, MD; Krishna Mukkamala, MD

07.21.25

The State of Geographic Atrophy Around the Globe: Part 2 of 2

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD

07.21.25

The State of Geographic Atrophy Around the Globe: Part 1 of 2

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD; Daniel Ting, MD, PhD

07.18.25

Diabetic Retinopathy Severity and Income Status

Ben Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD

07.07.25

GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy

Judy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD

07.07.25

GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

Judy Kim, MD; Sunir Garg, MD; Deepak Sambhara, MD; and Rishi Singh, MD

Show More